What question did this study set out to answer?

This study aims to determine if premenopausal HR+/HER2- breast cancer patients can safely omit chemotherapy after neoadjuvant endocrine therapy if they show an adequate response.

February 19, 2026Clinical Cancer Research

Abstract PS5-07-10: Young HOPE/JCOG2402: A Randomized Phase III Study of Response-Guided Therapy Following Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer

View Full Paper

Ask AI

Bookmark

This study aims to determine if premenopausal HR+/HER2- breast cancer patients can safely omit chemotherapy after neoadjuvant endocrine therapy if they show an adequate response.
Conduct a randomized phase III trial comparing upfront surgery to neoadjuvant endocrine therapy (NET) with specific eligibility criteria.
Stratify participants by clinical nodal status and histologic grade.
Administer NET for 3 months followed by surgery for those in the NET arm, monitoring for hormone receptor expression and Ki-67 levels.
Use chemotherapy for predefined high-risk patients in the upfront surgery arm, incorporating endocrine therapy with ovarian function suppression.
Estimated 5-year event-free survival in the upfront surgery arm is 92%.
Non-inferiority margin set at 3.4% with planned enrollment of 928 patients over 5 years.
Results suggest potential to omit chemotherapy for select patients achieving a favorable response after NET.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

A randomized phase III study evaluates event-free survival in premenopausal breast cancer, suggesting chemotherapy omission for specific responders.

Cite This Study

Ono et al. (2026) studied this question.

synapsesocial.com/papers/6996a8a9ecb39a600b3efa1f https://doi.org/10.1158/1557-3265.sabcs25-ps5-07-10

View Full Paper

Ask AI

Bookmark

Implication

A randomized phase III study evaluates event-free survival in premenopausal breast cancer, suggesting chemotherapy omission for specific responders.

Abstract PS5-07-10: Young HOPE/JCOG2402: A Randomized Phase III Study of Response-Guided Therapy Following Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Abstract PS5-07-10: Young HOPE/JCOG2402: A Randomized Phase III Study of Response-Guided Therapy Following Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider